½ÃÀ庸°í¼­
»óǰÄÚµå
1589796

¼¼°èÀÇ ¸» ÀǾàǰ ¹× º¸ÃæÁ¦ ½ÃÀå : Á¦Ç°º°, À¯Åë ä³Îº° ¿¹Ãø(2025-2030³â)

Equine Pharmaceuticals & Supplements Market by Product (Pharmaceutical, Supplement), Distribution Channel (Drug Stores, Veterinary Hospitals) - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 198 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¸» ÀǾàǰ ¹× º¸ÃæÁ¦ ½ÃÀåÀº 2023³â¿¡ 9¾ï 3,052¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 9¾ï 8,349¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 5.78%·Î ¼ºÀåÇØ 2030³â¿¡´Â 13¾ï 7,952¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸» ÀǾàǰ ¹× º¸ÃæÁ¦ ½ÃÀå¿¡´Â ¸»ÀÇ °Ç°­ÀÇ À¯Áö¡¤ÁõÁøÀ» ¸ñÀûÀ¸·Î ÇÑ ÀǾàǰ, ¿µ¾ç º¸ÃæÁ¦, ¼öÀÇ·áÀû Ä¡·á µî ¸» Àü¿ëÀ¸·Î ¹èÇÕµÈ ´Ù¾çÇÑ Á¦Ç°ÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ Á¦Ç°ÀÇ Çʿ伺Àº ÁÖ·Î ¸»ÀÌ ½ºÆ÷Ã÷, ³ó¾÷ ¹× ·¹Àú Ȱµ¿¿¡ ±¤¹üÀ§ÇÏ°Ô Âü¿©Çϰí ÃÖÀûÀÇ °Ç°­°ú ¼º´ÉÀ» ¿ä±¸Çϱ⠶§¹®¿¡ ¹ß»ýÇÕ´Ï´Ù. ±× ¿ëµµ´Â Çʼö ¿µ¾ç¼ÒÀÇ º¸±ÞÀ̳ª °üÀý¡¤»ÀÀÇ °Ç°­ °ü¸®·ÎºÎÅÍ, ƯÁ¤ÀÇ º´¸®ÀÇ Ä¡·á±îÁö ´Ù¾çÇÕ´Ï´Ù. ¼öÀÇ»ç, ½Â¸¶ ¿ä¹ý»ç, »çÀ°ÀÚ ¹× ¸¶ÁÖ°¡ ÁÖ¿ä ÃÖÁ¾ »ç¿ëÀÚÀÌ¸ç ¸» »ê¾÷¿¡¼­ ÀÌ·¯ÇÑ Á¦Ç°ÀÇ Á߿伺À» µÞ¹ÞħÇÕ´Ï´Ù. ½ÃÀåÀÇ ¼ºÀåÀº ¸»ÀÇ °Ç°­¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡, ¸»ÀÇ Áúº´ À¯º´·ü Áõ°¡, õ¿¬ ¼ººÐ°ú Á¦Á¦¿¡ ´ëÇÑ ÁöÇâ Áõ°¡ µîÀÇ ¿äÀο¡ °­ÇÏ°Ô ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ¸¶¼ú ½ºÆ÷Ã÷ »ê¾÷ÀÇ È®´ëµµ ½ÃÀå ¼ö¿ä¿¡ Å« ź·ÂÀ» °¡Çϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ½ÃÀåÀº ¼ººÐ ºñ¿ëÀÇ º¯µ¿, ¾ö°ÝÇÑ ±ÔÁ¦ »óȲ, Á¦Ç°ÀÇ À¯È¿¼ºÀ» °ËÁõÇϱâÀ§ÇÑ Á¾ÇÕÀûÀÎ Á¶»çÀÇ Çʿ伺°ú °°Àº °úÁ¦¿¡ Á÷¸éÇϰí ÀÖ½À´Ï´Ù. ÀÌ ºÐ¾ßÀÇ Çõ½ÅÀº º¸ÃæÁ¦ÀÇ Ã·´Ü Àü´Þ ½Ã½ºÅÛ °³¹ß, ½Å±Ô Ä¡·á¸¦ À§ÇÑ »ý¸í°øÇÐÀÇ Áøº¸ Ȱ¿ë, °³ÀÎÈ­µÈ ¸» °Ç°­ °ü¸®¸¦ À§ÇÑ µ¥ÀÌÅÍ ºÐ¼® Ȱ¿ë¿¡ ÁßÁ¡À» µÑ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ Æ¯Á¤ ǰÁ¾°ú º´Å¿¡ ƯȭµÈ Á¦Á¦ÀÇ ¿¬±¸ °³¹ßµµ »ý°¢ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÎ¹®¿¡ ÁøÀÔÇÏ´Â ±â¾÷Àº À¯ÅëÀ» °­È­ÇÏ°í Æ´»õ ½ÃÀåÀ» ´ë»óÀ¸·Î ÇÑ Á¦Ç° ¶óÀÎÀ» È®´ëÇϱâ À§ÇØ Àü·«Àû ÆÄÆ®³Ê½Ê°ú Á¦ÈÞ¸¦ °í·ÁÇØ¾ßÇÕ´Ï´Ù. ¸¶¼ú °æ±â°¡ Ȱ¹ßÇØÁö°í ÀÖ´Â ¹Ì°³Ã´ Áö¿ª¿¡µµ ÀáÀçÀûÀÎ ºñÁî´Ï½º ±âȸ°¡ Á¸ÀçÇϱ⠶§¹®¿¡ ±â¾÷Àº ½ÃÀå¿¡ÀÇ Ä§Åõ¿Í ¼ÒºñÀÚ ±³À°À» È¿°úÀûÀ¸·Î ÇÏ´Â Àü·«À» ¼¼¿ö¾ß ÇÕ´Ï´Ù. ½ÃÀåÀº ±âÁ¸±â¾÷°ú ½ÅÈï±â¾÷ ¸ðµÎ Á¸ÀçÇϸç ÀϰüµÈ ±â¼ú Çõ½Å°ú ǰÁú¿¡ ´ëÇÑ °íÁýÀÌ ÇÊ¿äÇÑ °æÀïȯ°æÀÌ ¾ç¼ºµÇ°í ÀÖ½À´Ï´Ù. °úÁ¦°¡ ÀÖ´Â °Í, ¸» ÀǾàǰ°ú º¸ÃæÁ¦ÀÇ ºÎ¹®Àº Àü¹®ÀûÀ̰í Áö¼Ó °¡´ÉÇÑ ¼Ö·ç¼Ç¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¼ö¿ä¿¡ °ßÀÎµÇ¾î ¼ºÀåÀ» Ãß±¸Çϰí ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ (2023³â) 9¾ï 3,052¸¸ ´Þ·¯
¿¹Ãø³â(2024³â) 9¾ï 8,349¸¸ ´Þ·¯
¿¹Ãø³â(2030³â) 13¾ï 7,952¸¸ ´Þ·¯
CAGR(%) 5.78%

½ÃÀå ¿ªÇÐ: ±Þ¼ÓÈ÷ ÁøÈ­ÇÏ´Â ¸» ÀǾàǰ ¹× º¸ÃæÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

¸» ÀǾàǰ ¹× º¸ÃæÁ¦ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÅõÀÚ°áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ ȹµæÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦ÀûÀÎ ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ½°ú µ¿½Ã¿¡, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ëÀ̳ª ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¸» ÀǾàǰ°ú º¸ÃæÁ¦ Á¦Ç°¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡
    • ¸» »çÀ°ÀÚ »çÀÌ¿¡¼­ À¯±â³ó Á¦Ç°ÀÌ ¼±ÅõǾî Çãºê »ç·á, ¼ÒÈ­Á¦, ¿¡³ÊÁö º¸ÃæÁ¦ ¼ö¿ä Áõ°¡
    • °æ¸¶³ª ¸¶¼ú ºÎ¹®¿¡¼­ÀÇ ¸» º¸ÃæÁ¦ÀÇ Ã¤¿ë È®´ë
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ÀǾàǰ°ú º¸ÃæÁ¦¿¡ °üÇÑ ¾ö°ÝÇÑ ±ÔÁ¦
  • ½ÃÀå ±âȸ
    • ¸»ÀÇ ÀüüÀûÀÎ °Ç°­°ú À£´Ï½º Áß½ÃÀÇ ³ô¾ÆÁü°ú ÀüÇØÁú º¸ÃæÁ¦ÀÇ ±¤¹üÀ§ÇÑ »ç¿ë
    • »õ·Î¿î ¸» ÀǾàǰ ¹× º¸ÃæÁ¦ÀÇ °³¹ß
  • ½ÃÀåÀÇ °úÁ¦
    • ¸»ÀÇ °Ç°­¿¡ ºÎÀÛ¿ë

Porter's Five Forces : ¸» ÀǾàǰ ¹× º¸ÃæÁ¦ ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces Framework´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Çϰí ÀÖ½À´Ï´Ù. ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ´ç½ÅÀº ´õ °­ÀÎÇÑ ½ÃÀå¿¡¼­ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¸» ÀǾàǰ ¹× º¸ÃæÁ¦ ½ÃÀå¿¡¼­ ¿ÜºÎ·ÎºÎÅÍÀÇ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¸» ÀǾàǰ ¹× º¸ÃæÁ¦ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇϴµ¥ À־ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÏ¸é ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ¾ÕÀ¸·Î ¿¹»óÇÑ Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ°¡ µÇ¾î ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ¸» ÀǾàǰ ¹× º¸ÃæÁ¦ ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

¸» ÀǾàǰ ¹× º¸ÃæÁ¦ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. Æ÷Áö¼Å´× ºÎµå·´°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ºÎ¹® È­ ¹× ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í °ø±Þ¾÷ü´Â °æÀïÀÌ Ä¡¿­ ÇØÁü¿¡ µû¶ó ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸± Çʿ䰡 ÀÖ½À´Ï´Ù. Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : ¸» ÀǾàǰ ¹× º¸ÃæÁ¦ ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¸» ÀǾàǰ ¹× º¸ÃæÁ¦ ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ Çà·ÄÀ» ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ : ¸» ÀǾàǰ ¹× º¸ÃæÁ¦ ½ÃÀå¿¡¼­ ¼º°ø¿¡ ´ëÇÑ ±æÀ» ±×¸³´Ï´Ù.

¸» ÀǾàǰ ¹× º¸ÃæÁ¦ ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ À־ ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ´É·Â ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í °³¼±À» À§ÇØ ³ë·ÂÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ Á¢±Ù¹ýÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ¸¶·ÃÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ ´Ù·ç´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ: ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·ÂÀ» Æò°¡ÇÕ´Ï´Ù.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÎ¹®¿¡¼­ÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» ¼³¸íÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­: ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, »ê¾÷ÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾òÀº ÈÄ ÀÇ»ç°áÁ¤ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡µµ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ¸» ÀǾàǰ°ú º¸ÃæÁ¦ Á¦Ç°¿¡ ´ëÇÑ ÀÎÁöµµ Çâ»ó
      • ¸» »çÀ°ÀÚµé »çÀÌ¿¡¼­ À¯±â³ó Á¦Ç°À» ¼±È£ÇÏ°Ô µÇ¾î, Çãºê »ç·á, ¼ÒÈ­Á¦, ¿¡³ÊÁö º¸ÃæÁ¦ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ´Ù
      • °æ¸¶¿Í ¸¶¼ú ºÎ¹®¿¡¼­ÀÇ ¸» º¸ÃæÁ¦ÀÇ Ã¤¿ë Áõ°¡
    • ¾ïÁ¦¿äÀÎ
      • ÀǾàǰÀ̳ª º¸ÃæÁ¦¿¡ °üÇÑ ¾ö°ÝÇÑ ±ÔÁ¦
    • ±âȸ
      • ¸»ÀÇ Á¾ÇÕÀûÀÎ °Ç°­°ú À£´Ï½º¿¡ÀÇ ÁßÁ¡ÀÌ ³ô¾ÆÁ®, ÀüÇØÁú º¸ÃæÁ¦°¡ ³Î¸® »ç¿ëµÇ°Ô µÇ¾ú½À´Ï´Ù
      • »õ·Î¿î ¸» ÀǾàǰ ¹× º¸ÃæÁ¦ÀÇ °³¹ß
    • °úÁ¦
      • ¸»ÀÇ °Ç°­¿¡ ºÎÀÛ¿ë
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ¸» ÀǾàǰ ¹× º¸ÃæÁ¦ ½ÃÀå : Á¦Ç°º°

  • ¼Ò°³
  • ÀǾàǰ
    • Ç׿°Áõ
    • Çױ˾çÁ¦
    • ÁøÁ¤Á¦¿Í Á¤½Å¾ÈÁ¤Á¦
  • º¸ÃæÁ¦
    • °üÀý º¸ÃæÁ¦
    • ºñŸ¹Î°ú ¹Ì³×¶ö

Á¦7Àå ¸» ÀǾàǰ ¹× º¸ÃæÁ¦ ½ÃÀå : À¯Åë ä³Îº°

  • ¼Ò°³
  • ¾à±¹
  • µ¿¹°º´¿ø

Á¦8Àå ¾Æ¸Þ¸®Ä«ÀÇ ¸» ÀǾàǰ ¹× º¸ÃæÁ¦ ½ÃÀå

  • ¼Ò°³
  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦9Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¸» ÀǾàǰ ¹× º¸Ãæ ½ÃÀå

  • ¼Ò°³
  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦10Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¸» ÀǾàǰ ¹× º¸Ãæ ½ÃÀå

  • ¼Ò°³
  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦11Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023³â
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • Alltech
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Cargill, Incorporated
  • Ceva Sante Animale
  • Dechra Veterinary Products Limited
  • Elanco Animal Health Incorporated
  • Equineproducts-uk Ltd.
  • Lallemand, Inc.
  • Merck & Co., Inc.
  • Purina Animal Nutrition LLC
  • Thermo Fisher Scientific Inc.
  • Vetoquinol USA
  • Virbac
  • Zoetis Inc.
JHS 24.11.21

The Equine Pharmaceuticals & Supplements Market was valued at USD 930.52 million in 2023, expected to reach USD 983.49 million in 2024, and is projected to grow at a CAGR of 5.78%, to USD 1,379.52 million by 2030.

The equine pharmaceuticals and supplements market encompasses a diverse range of products that are formulated specifically for horses, including medications, nutritional supplements, and veterinary treatments aimed at maintaining and enhancing equine health. The necessity of these products emerges primarily from the extensive participation of equines in sports, agriculture, and leisure activities, which demands optimum health and performance. Applications range from providing essential nutrients and managing joint and bone health to treating specific medical conditions. Veterinarians, equine therapists, breeders, and horse owners represent the primary end-users, underlining the importance of these products in the equine industry. Market growth is strongly influenced by factors such as increasing awareness regarding horse health, the rising prevalence of equine diseases, and a growing inclination towards natural ingredients and formulations. Moreover, the expanding equestrian sports industry adds significant impetus to market demand. However, the market faces challenges such as fluctuating ingredient costs, stringent regulatory landscapes, and the need for comprehensive research to validate product efficacy. Innovations in this domain could focus on developing advanced delivery systems for supplements, leveraging biotechnological advancements for novel therapeutics, and utilizing data analytics for personalized equine health management. R&D efforts could also explore tailored formulations for specific breeds or conditions. Companies venturing into this space should consider strategic partnerships or collaborations for enhanced distribution and expanded product lines targeting niche markets. Potential opportunities exist within the untapped regions where equine sports are gaining traction, requiring companies to strategize market penetration and consumer education effectively. The market is characterized by both established firms and emerging players, fostering a competitive environment that necessitates consistent innovation and adherence to quality. Despite challenges, the equine pharmaceuticals and supplements sector is poised for growth, driven by continuous demand for specialized and sustainable solutions.

KEY MARKET STATISTICS
Base Year [2023] USD 930.52 million
Estimated Year [2024] USD 983.49 million
Forecast Year [2030] USD 1,379.52 million
CAGR (%) 5.78%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Equine Pharmaceuticals & Supplements Market

The Equine Pharmaceuticals & Supplements Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing awareness about equine pharmaceuticals and supplements products
    • Rising demand for herbal feed, digestive, and energy supplements owing to the choice among horse breeders for organic products
    • Growing adoption of equine supplements in horse racing and equestrian sectors
  • Market Restraints
    • Stringent regulations regarding the pharmaceutical products and supplements
  • Market Opportunities
    • Growing emphasis on overall equine health and wellness, and extensively use of electrolyte supplements
    • Development of new equine pharmaceuticals & supplements
  • Market Challenges
    • Side effects on the health of equine

Porter's Five Forces: A Strategic Tool for Navigating the Equine Pharmaceuticals & Supplements Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Equine Pharmaceuticals & Supplements Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Equine Pharmaceuticals & Supplements Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Equine Pharmaceuticals & Supplements Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Equine Pharmaceuticals & Supplements Market

A detailed market share analysis in the Equine Pharmaceuticals & Supplements Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Equine Pharmaceuticals & Supplements Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Equine Pharmaceuticals & Supplements Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Equine Pharmaceuticals & Supplements Market

A strategic analysis of the Equine Pharmaceuticals & Supplements Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Equine Pharmaceuticals & Supplements Market, highlighting leading vendors and their innovative profiles. These include Alltech, Bayer AG, Boehringer Ingelheim International GmbH, Cargill, Incorporated, Ceva Sante Animale, Dechra Veterinary Products Limited, Elanco Animal Health Incorporated, Equineproducts-uk Ltd., Lallemand, Inc., Merck & Co., Inc., Purina Animal Nutrition LLC, Thermo Fisher Scientific Inc., Vetoquinol USA, Virbac, and Zoetis Inc..

Market Segmentation & Coverage

This research report categorizes the Equine Pharmaceuticals & Supplements Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Pharmaceutical and Supplement. The Pharmaceutical is further studied across Anti-Inflammatory, Anti-Ulcer Drugs, and Sedative & Tranquilizer. The Supplement is further studied across Joint Supplements and Vitamins & Minerals.
  • Based on Distribution Channel, market is studied across Drug Stores and Veterinary Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing awareness about equine pharmaceuticals and supplements products
      • 5.1.1.2. Rising demand for herbal feed, digestive, and energy supplements owing to the choice among horse breeders for organic products
      • 5.1.1.3. Growing adoption of equine supplements in horse racing and equestrian sectors
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulations regarding the pharmaceutical products and supplements
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing emphasis on overall equine health and wellness, and extensively use of electrolyte supplements
      • 5.1.3.2. Development of new equine pharmaceuticals & supplements
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects on the health of equine
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Equine Pharmaceuticals & Supplements Market, by Product

  • 6.1. Introduction
  • 6.2. Pharmaceutical
    • 6.2.1. Anti-Inflammatory
    • 6.2.2. Anti-Ulcer Drugs
    • 6.2.3. Sedative & Tranquilizer
  • 6.3. Supplement
    • 6.3.1. Joint Supplements
    • 6.3.2. Vitamins & Minerals

7. Equine Pharmaceuticals & Supplements Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Drug Stores
  • 7.3. Veterinary Hospitals

8. Americas Equine Pharmaceuticals & Supplements Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Equine Pharmaceuticals & Supplements Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Equine Pharmaceuticals & Supplements Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alltech
  • 2. Bayer AG
  • 3. Boehringer Ingelheim International GmbH
  • 4. Cargill, Incorporated
  • 5. Ceva Sante Animale
  • 6. Dechra Veterinary Products Limited
  • 7. Elanco Animal Health Incorporated
  • 8. Equineproducts-uk Ltd.
  • 9. Lallemand, Inc.
  • 10. Merck & Co., Inc.
  • 11. Purina Animal Nutrition LLC
  • 12. Thermo Fisher Scientific Inc.
  • 13. Vetoquinol USA
  • 14. Virbac
  • 15. Zoetis Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦